The University of Tokyo

Next21 K.k.

Nof Corporation

Matsuura Machinery Corporation

Nanocarrier Co., Ltd.

Yuichi Tei

Nobuo Sasaki

Shigeki Suzuki

Takamasa Sakai

Kazunori Kataoka

Nobuhiro Nishiyama

Koichi Amaya

Hideto Matsubara

Keiji Itaka

Takuya Hashimoto

Yukinori Urushizaki

Hiroyuki Koyama

Shourong Wu

Ryosuke Echigo

Touru Hakukawa

Nobuo Saski

Shinsuke Ohba

An object of the present invention is to provide a gel material including a solvophilic polymer having a μm-scale porous structure. A polymer gel in which solvophilic polymer units are cross-linked with each other, wherein the polymer gel contains a solvent and has a three-dimensional network structure having two regions: a first region in which the polymer units are densely present and a second region in which the polymer units are sparsely present, and a mesh size composed of the first region is from 1 to 500 μm.

Polymer gel having sponge-like porous structure

[Problem] To provide a gel which can be produced in a short time, has controlled properties such as modulus and expansion pressure, and has a low polymer concentration. [Solution] A process for producing a polymer gel in which gel-precursor clusters have been crosslinked with one another to form a three-dimensional network structure, characterized by comprising a) a step in which monomer or polymer units that are present in a concentration less than a critical gelation concentration are crosslinked to form the gel-precursor clusters, the gel-precursor clusters having a storage modulus G' and a loss modulus G&#x2033; which satisfy the relationship G&#x2032;&#x3c;G&#x2033;, and b) a step in which the gel-precursor clusters are crosslinked with one another by a crosslinking agent to obtain a gel having a three-dimensional network structure.

Process for producing low-concentration gel using gel-precursor clusters, and gel obtained by said production process

A method of manufacturing a medical drug of alleviating damage of gastrointestinal mucosal induced by a non-steroidal anti-inflammatory drug, NSAID, the medical drug being able to induce anti-inflammatory effect of the NSAID and being able to alleviate damage induced by the NSAID includes dissolving trehalose and the NSAID into one or more solutions, so as to obtain an approximately homogenously-mixed liquid mixture of the trehalose and the NSAID; in which the liquid mixture contains an intermolecular compound with the trehalose and the NSAID; and drying the liquid mixture so as to obtain the medical drug.

NSAIDs-induced gastrointestinal mucosal disorder alleviator and manufacturing method thereof

Disclosed is a respiration-assisting tube whereby tissue damages in vivo can be prevented and, as a result, inflammatory reactions and infections can be avoided. The respiration-assisting tube is developed based on the finding that adhesion of cells to a respiration-assisting tube can be inhibited by coating the respiration-assisting tube with a polymer containing 2-methacryloyloxyethyl phosphorylcholine (MPC). Also, the respiration-assisting tube is developed based on the finding that, by coating a respiration-assisting tube with a polymer containing MPC, mucosa peeling and tissue damages, which occur after using the respiration-assisting tube, can be prevented and, as a result, inflammatory reactions can be avoided.

Resin product for medical use and respiration-assisting tube

Disclosed is an artificial bone material having controlled calcium ion elution, which does not induce cytotoxicity or any inflammatory response. It is found that the elution of a calcium ion from an artificial bone material for transplantation which contains a calcium-containing substance can be prevented effectively by subjecting the carrier to a surface treatment or adding a surface-treating agent to the carrier. It is also found that the induction of cytotoxicity can be prevented and the induction of an inflammatory response can also be prevented by using the above-mentioned carrier having controlled calcium ion elution.

Artificial bone material having controlled calcium ion elution

The present invention aims to provide a gene delivery system with higher safety and higher sustainability, which is effective for the treatment of ischemic diseases and the like, and the like. The present invention provides a pharmaceutical composition containing, as an active ingredient, a polyanionic substance that suppresses expression of PHD2, and containing a polyion complex of the polyanionic substance and a polycation chargeable polymer.

Polyion complex comprising PHD2 expression inhibiting substance

A method for producing an artificial bone capable of accurate molding at a joined part with appropriate strength, in which electromagnetic waves or electron beams are irradiated to a layer of at least type of powder selected from metal biomaterials, ceramics for the artificial bone and plastic resins for the artificial bone based on image data corresponding to a shape of the artificial bone, thereby effecting sintering or melting, and the thus sintered layer or melted and solidified layer is laminated, such that a surface finish step is adopted that inner faces and/or outer faces of both ends and their vicinities configuring the joined part to a human bone part are polished by a rotating tool based on the image data and also irradiation of electromagnetic waves or electron beams at both ends and their vicinities constituting the joined part is set greater than that at other regions.

Method for producing artificial bone and artificial bone produced by the method

An object of the present invention is to provide an agent for treating or preventing vasospasm. An object of the present invention is to provide an agent for treating or preventing cerebral vasospasm as well as arterial vasospasm. Further, an object of the present invention is to provide an agent for treating or preventing cerebral ischemia and cerebral infarction. The above problems are solved by an agent for treating and preventing vasospasm, cerebral ischemia, or cerebral infarction, comprising trehalose as the active ingredient. It is possible, by using such a trehalose-comprising agent, to suppress phenomena such as contraction of blood vessel and thickening of tunica intima and tunica media and to prevent or treat vasospasm and vasospasm-dependent diseases.

Growing community of inventors

Tokyo, Japan

Yuichi Tei